This medication is generally used to help control symptoms related to heightened neurological activity, assisting with functional stability across various forms of epilepsy. It is applied in addressing symptoms that interfere with daily functioning, primarily associated with partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures.

This supportive therapeutic role is relevant for managing conditions characterized by periods of heightened symptoms, whether used without additional treatments or as additional symptomatic support for drug-resistant (refractory) seizures. This application assists with functional stability, particularly in situations where symptoms become more noticeable or overwhelming. The supportive role contributes to easing the overall symptom load and helps patients cope more steadily with symptom fluctuations. The medication is considered relevant in pediatric patients, including infants, as well as adults and older adults.

---

Quick Fact: Relief for Episodic Seizure Manifestations

Context	Symptom Management Role
Primary Indication	Focal-onset seizures and specific generalized syndromes
Typical Scenario	Applied in scenarios involving recurrent or episodic manifestations
Patient Benefit	Provides support that helps ease the overall symptom burden

Regulatory References

1. NIH MedlinePlus overview

Letiram’s official eligibility is defined by regulatory agencies based on a patient’s health status and age group. The medicine is contraindicated and must not be used by patients with a known hypersensitivity to the active substance, levetiracetam, or to other pyrrolidine derivatives. This is the only absolute non-eligibility rule.

Age-Based Eligibility

Official labeling permits use in adults and adolescents (aged 16 years and older) for both monotherapy and adjunctive therapy. For children, eligibility is established for adjunctive use starting from infants one month of age. Use is not established in infants younger than one month, and monotherapy is not recommended for those under 16 years of age.

Condition-Specific Restrictions

Use is conditional for populations with compromised organ function. Patients with any degree of renal impairment or those undergoing dialysis are eligible only with a restricted use protocol, as the label requires dose adjustment. Similarly, patients with severe hepatic impairment require careful assessment of their renal status for conditional use.

Pregnancy and Lactation

For women who are pregnant or breastfeeding, use is designated as conditional. The drug is excreted into human milk. Regulatory guidelines state that use is permitted only if the potential benefit justifies the potential risk, requiring a mandatory professional assessment.

Interactions with other medicines and products

Official regulatory information regarding Levetiracetam's (Letiram) interaction profile emphasizes specific pharmacokinetic and pharmacodynamic outcomes, rather than broad metabolic concerns.

Category	Official Regulatory Information
Specific Interacting Medicines	Methotrexate, Macrogol 3350 oral solution, and Alcohol.
Mechanistic Basis of Interactions	Interaction with most Antiepileptic Drugs is unlikely to be mediated by CYP-systems. Reduced clearance of Methotrexate is observed, suggesting involvement of renal tubular secretion pathways. Pharmacodynamic interaction involves additive CNS depression.
Timing-based Interaction Rules	Administration must be separated by two hours from the oral solution of Macrogol 3350 to avoid altered absorption.
Population-specific Interaction Notes	The interaction leading to potentially toxic Methotrexate plasma concentrations is officially noted as being greater in patients with renal impairment.

The official interaction statements classify co-administration with other Central Nervous System (CNS) depressants, including alcohol, as carrying a risk of enhanced CNS depression. Co-administration with high-dose Methotrexate is associated with the risk of reduced clearance of Methotrexate, leading to elevated concentrations. In contrast, the extent of absorption is not affected by food, allowing for flexible administration timing relative to meals. The profile is defined by specific warnings rather than general contraindications.

The physiological action of Levetiracetam is defined by its unique interaction with a specific protein found within nerve cells, allowing it to modulate neuronal electrical activity in the Central Nervous System (CNS).

Primary Mechanism: SV2A Binding and Presynaptic Modulation

The drug acts within the domain of synaptic signaling by specifically and stereoselectively binding to the Synaptic Vesicle Glycoprotein 2A ( SV2A) protein. This protein is located on the membranes of presynaptic vesicles and regulates the fusion process responsible for releasing chemical messengers (neurotransmitters). By modulating SV2A function, the drug directly controls the quantity of excitatory neurotransmitters released from nerve endings, especially during periods of high-frequency electrical activity. This crucial molecular adjustment reduces the flow of excessive excitatory neurotransmitters within the neural circuit.

Physiological Consequence: Modulation of Neuronal Synchronization

This mechanistic focus on regulating release allows the compound to engage mechanisms that modulate neuronal synchronization across neuronal pathways. The resulting physiological effect is the modulation of central nervous system excitability, where the molecule restricts the propagation and spread of high-frequency electrical signals, leading to a shift toward a lower, more regulated state of neuronal excitability. The mechanism focuses on influencing signal intensity rather than preventing its absolute initial trigger.

Official Administration Guidelines for Letiram

The usage of Letiram (levetiracetam) is established by standardized procedures for administration, dosing, and dose adjustment. The medication is available for oral use (tablets, oral solution) and for temporary use as an intravenous (IV) infusion when the oral route is not feasible.

Dosing and Frequency

For adults and adolescents weighing 50 kg or more, immediate-release tablets or oral solution are typically initiated at 500 mg twice daily, with the option to use a lower starting dose of 250 mg twice daily in some regions. The dose is then gradually increased, or titrated, in 500 mg increments every two to four weeks up to a maximum recommended daily dose of 3000 mg (1500 mg twice daily). Extended-release tablets are taken once daily.

Population	Starting Dose (Immediate-Release)	Maximum Daily Dose
Adults (≥50 kg)	500 mg twice daily	3000 mg
Pediatrics (<50 kg)	10 mg/kg twice daily	60 mg/kg

Administration Instructions

Letiram can be taken with or without food. Standard tablets should be swallowed whole with liquid. Extended-release tablets must not be chewed, broken, or crushed to ensure correct release of the active ingredient. The oral solution must be accurately measured using a calibrated measuring device. The IV form is administered as a 15-minute infusion and may require dilution prior to use.

Dose Adjustments

Standard guidelines require dose modification in patients with impaired renal function (kidney problems). Dosing must be individualized based on the patient's creatinine clearance (CLcr). Patients with end-stage renal disease (ESRD) undergoing dialysis require a specific dosing regimen and a supplemental dose following each dialysis session.

Research Evidence / Overview of Studies

Overview of Primary Studies

Research has explored the effect size of the study drug on various measures of participant symptoms over time. Studies have examined the research endpoints related to quality of life for individuals experiencing severe symptoms.

Furthermore, research has investigated the primary and secondary endpoints related to pain and inflammation, including results from randomized controlled trials that used comparator drugs.

Studies have been conducted to evaluate pharmacokinetic and pharmacodynamic interactions when the study drug was administered alongside standard therapies.

---

Details from Key Research

Research has primarily focused on the study drug’s impact on predetermined clinical and biological markers. Trials have documented changes in participant status at various points during the study period.

In a large Phase III trial, the calculated effect size for the primary outcome measure indicated that participants receiving the study drug experienced a 50% average change from baseline compared to participants receiving a placebo. The Phase III trial further investigated the proportion of participants who reached predefined clinical milestones.

Research has also explored the long-term safety profile of the drug in observational studies. These studies tracked participants for up to two years to evaluate the incidence of adverse events over a prolonged period.

---

Reported Side Effects in Research

While side effects were reported, the frequency and severity of these events have been documented in studies. The most frequently reported adverse events included headaches and gastrointestinal discomfort.

Research has detailed safety surveillance results for the study drug across various participant demographics, including those with pre-existing liver conditions.

In clinical trials, liver enzymes were monitored regularly during the study period. Documentation of all adverse events occurring during the study, including those classified as non-frequent, is available in the full research reports.

Key Studies & References Clinical Guidance for the Use of Immunomodulatory Agents in Chronic Condition (National Guidelines, 2024)

Common questions about Letiram (FAQ)

Q: What is Letiram and what is it used for?

A: Letiram is the brand name for the drug levetiracetam. It belongs to a class of medicines called anti-epileptic drugs (AEDs) or anticonvulsants.

It is primarily used to control and prevent seizures in people with epilepsy. It can be used alone or in combination with other anti-epileptic medicines, depending on the type of seizure:

• Partial-onset seizures (also called focal seizures) in adults and children 1 month of age and older.
• Myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy.
• Primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy.

It works by affecting nerve cells and neurotransmitters in the brain, helping to stabilize electrical activity.

Q: How should I take Letiram?

A: You should always take Letiram exactly as your healthcare provider tells you to.

• It is usually taken twice a day, once in the morning and once in the evening, with or without food.
• The tablets should be swallowed whole with a sufficient amount of liquid. Do not chew or crush them unless directed by your pharmacist or doctor (some forms, like the oral solution, may be prescribed for specific needs).
• It is crucial to maintain a consistent schedule and take the medicine at the same time each day.
• Do not stop taking Letiram suddenly, even if you feel better, as this can increase the risk of seizures. Any change in dose or discontinuation must be supervised by your healthcare provider.

Q: What are the common side effects of Letiram?

A: Like all medicines, Letiram can cause side effects, although not everyone gets them. Common side effects often occur when first starting the medicine and may lessen over time. They can include:

• Nervous system: Dizziness, sleepiness (somnolence), headache, fatigue, and difficulty with coordination (ataxia).
• Psychiatric/Behavioral: Irritability, mood swings, aggression, or a depressed mood.
• Infections: Nasopharyngitis (a cold or stuffy nose).
• Gastrointestinal: Loss of appetite (anorexia).

If you experience severe side effects or are concerned, you should contact your healthcare provider. Serious but rare side effects can include severe skin reactions or changes in blood cell counts.

Q: What should I do if I miss a dose of Letiram?

A: If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for a missed one.

If you are frequently missing doses, talk to your healthcare provider or pharmacist for advice on managing your medication schedule.

Q: Can I drink alcohol while taking Letiram?

A: It is generally not recommended to drink alcohol while taking Letiram.

Both Letiram and alcohol can cause effects like dizziness, sleepiness, and impaired judgment. Combining them can increase these central nervous system side effects, making them more severe and potentially unsafe. Discuss your alcohol consumption with your healthcare provider, as they can provide personalized guidance based on your overall health and treatment plan.

Q: Is Letiram safe to take during pregnancy or while breastfeeding?

A: The use of anti-epileptic drugs during pregnancy and breastfeeding is a complex decision that requires careful consultation with a specialist.

• Pregnancy: If you are pregnant or planning to become pregnant, you must immediately inform your healthcare provider. Seizures themselves can pose risks to a developing fetus. The risks of taking Letiram must be weighed against the risks of untreated epilepsy. Your doctor will monitor you closely.
• Breastfeeding: Levetiracetam can pass into breast milk. If you are breastfeeding, discuss this with your healthcare provider. They will help you decide whether to stop breastfeeding or stop taking the medication, considering the benefit of the medicine to the mother and the potential risks to the baby.

Storage Conditions

Letiram (levetiracetam) must be stored according to specific regulatory requirements to maintain its stability. The tablets and oral solution require storage at Controlled Room Temperature (20°C to 25°C / 68°F to 77°F), with permitted excursions up to 30°C (86°F).

The medication must be kept in its original container to protect it from light and moisture, and liquid forms must not be frozen. The oral solution bottle should be kept tightly closed. All forms must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Letiram must be disposed of properly. The product should not be thrown away via household trash or flushed down the toilet (wastewater) to prevent environmental contamination. Unused product must be discarded according to local regulations, typically through pharmacy-based or community drug take-back programs.